Uncommon yeast infections in hematological patients: from diagnosis to treatment

References

• Pagano L, Caira M, Nosari A et al. Fungal infections in recipients of hematopoietic stem cell transplants: results of the SEIFEM B-2004 study – Sorveglianza Epidemiologica Infezioni Fungine Nelle Emopatie Maligne. Clin. Infect. Dis.45(9), 1161–1170 (2007).
   PubMed Web of Science ®Google Scholar
• Pagano L, Caira M, Nosari A et al. Fungal infections in recipients of hematopoietic stem cell transplants: results of the SEIFEM B-2004 study. Clin. Infect. Dis.45, 1161–1170 (2007).
   PubMed Web of Science ®Google Scholar
• de Pauw BE. What are fungal infections? Mediterr. J. Hematol. Infect. Dis.3(1), e2011001 (2011).
   PubMedGoogle Scholar
• Caira M, Mancinelli M, Leone G, Pagano L. Invasive aspergillosis in acute leukemias: old and new risk factors and epidemiological trends. Med. Mycol.49(Suppl. 1), S13–S16 (2011).
   PubMed Web of Science ®Google Scholar
• Cornely OA. Aspergillus to Zygomycetes: causes, risk factors, prevention, and treatment of invasive fungal infections. Infection36(4), 296–313 (2008).
   PubMed Web of Science ®Google Scholar
• Caira M, Girmenia C, Fadda RM et al. Invasive fungal infections in patients with acute myeloid leukemia and in those submitted to allogeneic hemopoietic stem cell transplant: who is at highest risk? Eur. J. Haematol.81(3), 242–243 (2008).
   PubMedGoogle Scholar
• Shang ST, Yang YS, Peng MY. Nosocomial Trichosporon asahii fungemia in a patient with secondary hemochromatosis: a rare case report. J. Microbiol. Immunol. Infect.43(1), 77–80 (2010).
   PubMedGoogle Scholar
• Richardson M. Changing epidemiology of systemic fungal infections. Clin. Microbiol. Infect.14(Suppl. 4), 5–24 (2008).
   PubMed Web of Science ®Google Scholar
• Enoch DA, Enoch DA, Ludlam HA, Brown NM. Invasive fungal infections: a review of epidemiology and management options. J. Med. Microbiol.55(Pt 7), 809–818 (2006).
   PubMed Web of Science ®Google Scholar
• Caira M, Trecarichi EM, Mancinelli M, Leone G, Pagano L. Uncommon mold infections in hematological patients: epidemiology, diagnosis and treatment. Expert Rev. Antinfect. Ther.9(7), 881–892 (2011).
   PubMed Web of Science ®Google Scholar
• Girmenia C, Pagano L, Martino B et al. Invasive infections caused by Trichosporon species and Geotrichum capitatum in patients with hematological malignancies: a retrospective multicenter study from Italy and review of the literature. J. Clin. Microbiol.43(4), 1818–1828 (2005).
   PubMed Web of Science ®Google Scholar
• Pagano L, Fianchi L, Caramatti C et al. Cryptococcosis in patients with hematologic malignancies. A report from GIMEMA-infection. Haematologica89(7), 852–856 (2004).
   PubMed Web of Science ®Google Scholar
• Chagas-Neto TC, Chaves GM, Colombo AL. Update on the genus Trichosporon. Mycopathologia166(3), 121–132 (2008).
   PubMed Web of Science ®Google Scholar
• Winston DJ, Balsley GE, Rhodes J, Linné SR. Disseminated Trichosporon capitatum infection in an immunosuppressed host. Arch. Intern. Med.137(9), 1192–1195 (1977).
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Groll A, Hiemenz J, Fleming R, Roilides E, Anaissie E. Infections due to emerging and uncommon medically important fungal pathogens. Clin. Microbiol. Infect.10(Suppl. 1), 48–66 (2004).
   PubMed Web of Science ®Google Scholar
• Groll AH, Walsh TJ. Uncommon opportunistic fungi: new nosocomial threats. Clin. Microbiol. Infect.7(Suppl. 2), 8–24 (2001).
   PubMed Web of Science ®Google Scholar
• Pagano L, Caira M, Fianchi L. Pulmonary fungal infection with yeasts and pneumocystis in patients with hematological malignancy. Ann. Med.37(4), 259–269 (2005).
   PubMed Web of Science ®Google Scholar
• Ruan SY, Chien JY, Hsueh PR. Invasive trichosporonosis caused by Trichosporon asahii and other unusual Trichosporon species at a medical center in Taiwan. Clin. Infect. Dis.49(1), e11–e17 (2009).
   PubMed Web of Science ®Google Scholar
• Kontoyiannis DP, Torres HA, Chagua M et al. Trichosporonosis in a tertiary care cancer center: risk factors, changing spectrum and determinants of outcome. Scand. J. Infect. Dis.36(8), 564–569 (2004).
   PubMed Web of Science ®Google Scholar
• Miyakoshi S, Kusumi E, Matsumura T et al. Invasive fungal infection following reduced-intensity cord blood transplantation for adult patients with hematologic diseases. Biol. Blood Marrow Transplant.13(7), 771–777 (2007).
   PubMed Web of Science ®Google Scholar
• Suzuki K, Nakase K, Kyo T et al. Fatal Trichosporon fungemia in patients with hematologic malignancies. Eur. J. Haematol.84(5), 441–447 (2010).
   PubMed Web of Science ®Google Scholar
• Chagas-Neto TC, Chaves GM, Melo AS, Colombo AL. Bloodstream infections due to Trichosporon spp.: species distribution, Trichosporon asahii genotypes determined on the basis of ribosomal DNA intergenic spacer 1 sequencing, and antifungal susceptibility testing. J. Clin. Microbiol.47(4), 1074–1081 (2009).
   PubMed Web of Science ®Google Scholar
• Lacasse A, Cleveland KO. Trichosporon mucoides fungemia in a liver transplant recipient: case report and review. Transpl. Infect. Dis.11(2), 155–159 (2009).
   Google Scholar
• Netsvyetayeva I, Swoboda-Kopeć E, Paczek L et al.Trichosporon asahii as a prospective pathogen in solid organ transplant recipients. Mycoses52(3), 263–265 (2009).
   Google Scholar
• Gross JW, Kan VL. Trichosporon asahii infection in an advanced AIDS patient and literature review. AIDS22(6), 793–795 (2008).
   Google Scholar
• Jian DY, Yang WC, Chen TW, Lin CC. Trichosporon asahii following polymicrobial infection in peritoneal dialysis-associated peritonitis. Perit. Dial. Int.28(1), 100–101 (2008).
   Google Scholar
• Antachopoulos C, Papakonstantinou E, Dotis J et al. Fungemia due to Trichosporon asahii in a neutropenic child refractory to amphotericin B: clearance with voriconazole. J. Pediatr. Hematol. Oncol.27(5), 283–285 (2005).
   Google Scholar
• Ebright JR, Fairfax MR, Vazquez JA. Trichosporon asahii, a non-Candida yeast that caused fatal septic shock in a patient without cancer or neutropenia. Clin. Infect. Dis.33(5), E28–E30 (2001).
   Google Scholar
• O’Gorman C, McMullan R, Webb CH, Bedi A. Trichosporon asahii. Blood-stream infection in a non-cancer patient receiving combination antifungal therapy. Ulster Med. J.75(3), 226–227 (2006).
   Google Scholar
• Kim YJ, Kim SI, Kim YR, Park YM, Park YJ, Kang MW. Successful treatment of septic shock with purpura fulminans caused by Trichosporon asahii in an immunocompetent patient. Ann. Clin. Lab. Sci.37(4), 366–369 (2007).
   Google Scholar
• Rastogi VL, Nirwan PS. Invasive trichosporonosis due to Trichosporon asahii in a non-immunocompromised host: a rare case report. Indian J. Med. Microbiol.25(1), 59–61 (2007).
   Google Scholar
• Di Bonaventura G, Pompilio A, Picciani C, Iezzi M, D’Antonio D, Piccolomini R. Biofilm formation by the emerging fungal pathogen Trichosporon asahii: development, architecture, and antifungal resistance. Antimicrob. Agents Chemother.50(10), 3269–3276 (2006).
   PubMed Web of Science ®Google Scholar
• Miceli MH, Díaz JA, Lee SA. Emerging opportunistic yeast infections. Lancet Infect. Dis.11(2), 142–151 (2011).
   PubMed Web of Science ®Google Scholar
• Nagai H, Yamakami Y, Hashimoto A, Tokimatsu I, Nasu M. PCR detection of DNA specific for Trichosporon species in serum of patients with disseminated trichosporonosis. J. Clin. Microbiol.37(3), 694–699 (1999).
   Google Scholar
• Sugita T, Nakajima M, Ikeda R, Niki Y, Matsushima T, Shinoda T. A nested PCR assay to detect DNA in sera for the diagnosis of deep-seated trichosporonosis. Microbiol. Immunol.45(2), 143–148 (2001).
   Google Scholar
• Melcher GP, Reed KD, Rinaldi MG, Lee JW, Pizzo PA, Walsh TJ. Demonstration of a cell wall antigen cross-reacting with cryptococcal polysaccharide in experimental disseminated trichosporonosis. J. Clin. Microbiol.29(1), 192–196 (1991).
   PubMedGoogle Scholar
• Pagano L, Caira M, Valentini CG, Posteraro B, Fianchi L. Current therapeutic approaches to fungal infections in immunocompromised hematological patients. Blood Rev.24(2), 51–61 (2010).
   PubMed Web of Science ®Google Scholar
• Paphitou NI, Ostrosky-Zeichner L, Paetznick VL, Rodriguez JR, Chen E, Rex JH. In vitro antifungal susceptibilities of Trichosporon species. Antimicrob. Agents Chemother.46(4), 1144–1146 (2002).
   PubMed Web of Science ®Google Scholar
• Matsue K, Uryu H, Koseki M, Asada N, Takeuchi M. Breakthrough trichosporonosis in patients with hematologic malignancies receiving micafungin. Clin. Infect. Dis.42(6), 753–757 (2006).
   PubMed Web of Science ®Google Scholar
• Asada N, Uryu H, Koseki M, Takeuchi M, Komatsu M, Matsue K. Successful treatment of breakthrough Trichosporon asahii fungemia with voriconazole in a patient with acute myeloid leukemia. Clin. Infect. Dis.43(4), e39–e41 (2006).
   PubMed Web of Science ®Google Scholar
• Taj-Aldeen SJ, Al-Ansari N, El Shafei S et al. Molecular identification and susceptibility of Trichosporon species isolated from clinical specimens in Qatar: isolation of Trichosporon dohaense Taj-Aldeen, Meis & Boekhout sp. nov. J. Clin. Microbiol.47(6), 1791–1799 (2009).
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Diekema DJ, Gibbs DL et al. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: 10.5-year analysis of susceptibilities of noncandidal yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing. J. Clin. Microbiol.47(1), 117–123 (2009).
   PubMed Web of Science ®Google Scholar
• Anaissie EJ, Hachem R, Karyotakis NC et al. Comparative efficacies of amphotericin B, triazoles, and combination of both as experimental therapy for murine trichosporonosis. Antimicrob. Agents Chemother.38(11), 2541–2544 (1994).
   PubMed Web of Science ®Google Scholar
• Rieger C, Geiger S, Herold T, Nickenig C, Ostermann H. Breakthrough infection of Trichosporon asahii during posaconazole treatment in a patient with acute myeloid leukaemia. Eur. J. Clin. Microbiol. Infect. Dis.26(11), 843–845 (2007).
   Google Scholar
• Espinel-Ingroff A. In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature. Rev. Iberoam. Micol.20(4), 121–136 (2003).
   PubMedGoogle Scholar
• Akagi T, Yamaguti K, Kawamura T, Nakumura T, Kubo K, Takemori H. Breakthrough trichosporonosis in patients with acute myeloid leukemia receiving micafungin. Leuk. Lymphoma47(6), 1182–1183 (2006).
   PubMed Web of Science ®Google Scholar
• Bayramoglu G, Sonmez M, Tosun I, Aydin K, Aydin F. Breakthrough Trichosporon asahii fungemia in neutropenic patient with acute leukemia while receiving caspofungin. Infection36(1), 68–70 (2008).
   Google Scholar
• Li H, Lu Q, Wan Z, Zhang J. In vitro combined activity of amphotericin B, caspofungin and voriconazole against clinical isolates of Trichosporon asahii. Int. J. Antimicrob. Agents35(6), 550–552 (2010).
   PubMed Web of Science ®Google Scholar
• Li H, Qiao J, Wan Z, Zhang J. In vitro interaction of itraconazole with amphotericin B, caspofungin, and terbinafine against clinical isolates of Trichosporon asahii. Mycopathologia171(5), 345–348 (2010).
   Google Scholar
• Thompson GR 3rd, Wiederhold NP, Sutton DA, Fothergill A, Patterson TF. In vitro activity of isavuconazole against Trichosporon, Rhodotorula, Geotrichum, Saccharomyces and Pichia species. J. Antimicrob. Chemother.64(1), 79–83 (2009).
   PubMed Web of Science ®Google Scholar
• Guinea J, Recio S, Escribano P, Peláez T, Gama B, Bouza E. In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens. Antimicrob. Agents Chemother.54(9), 4012–4015 (2010).
   PubMed Web of Science ®Google Scholar
• Bouza E, Muñoz P. Invasive infections caused by Blastoschizomyces capitatus and Scedosporium spp. Clin. Microbiol. Infect.10(Suppl. 1), 76–85 (2004).
   PubMed Web of Science ®Google Scholar
• Celik AD, Ozaras R, Kantarcioglu S, Mert A, Tabak F, Ozturk R. Spondylodiscitis due to an emergent fungal pathogen: Blastoschizomyces capitatus, a case report and review of the literature. Rheumatol. Int.29(10), 1237–1241 (2009).
   Google Scholar
• Lapusan S, Dimicoli S, Marjanovic Z et al. Immune reconstitution inflammatory syndrome following Allo-SCT in a patient with Dipodascus capitatus spondylodiscitis. Bone Marrow Transplant.46(9), 1265–1267 (2010).
   Google Scholar
• Bonini A, Capatti C, Parmeggiani M et al. Galactomannan detection in Geotrichum capitatum invasive infections: report of 2 new cases and review of diagnostic options. Diagn. Microbiol. Infect. Dis.62(4), 450–452 (2008).
   PubMed Web of Science ®Google Scholar
• Martino P, Venditti M, Micozzi A et al.Blastoschizomyces capitatus: an emerging cause of invasive fungal disease in leukemia patients. Rev. Infect. Dis.12(4), 570–582 (1990).
   PubMedGoogle Scholar
• Giacchino M, Chiapello N, Bezzio S et al.Aspergillus galactomannan enzyme-linked immunosorbent assay cross-reactivity caused by invasive Geotrichum capitatum. J. Clin. Microbiol.44(9), 3432–3434 (2006).
   PubMed Web of Science ®Google Scholar
• Venditti M, Posteraro B, Morace G, Martino P. In vitro comparative activity of fluconazole and other antifungal agents against Blastoschizomyces capitatus. J. Chemother.3(1), 13–15 (1991).
   PubMed Web of Science ®Google Scholar
• Etienne A, Datry A, Gaspar N et al. Successful treatment of disseminated Geotrichum capitatum infection with a combination of caspofungin and voriconazole in an immunocompromised patient. Mycoses51(3), 270–272 (2008).
   PubMedGoogle Scholar
• Ikuta K, Torimoto Y, Yamamoto M et al. Successful treatment of systemic Geotrichum capitatum infection by liposomal amphotericin-B, itraconazole, and voriconazole in a Japanese man. Intern. Med.49(22), 2499–2503 (2010).
   PubMed Web of Science ®Google Scholar
• Adami F, Scarin M, Pescarini L et al. Successful control of Blastoschizomyces capitatus infection in three consecutive acute leukaemia patients despite initial unresponsiveness to liposomal amphotericin B. Mycoses54(4), 365–369 (2010).
   Google Scholar
• Hajjeh RA, Conn LA, Stephens DS et al. Cryptococcosis: population-based multistate active surveillance and risk factors in human immunodeficiency virus-infected persons. Cryptococcal Active Surveillance Group. J. Infect. Dis.179(2), 449–454 (1999).
   PubMed Web of Science ®Google Scholar
• Pappas PG, Perfect JR, Cloud GA et al. Cryptococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapy. Clin. Infect. Dis.33(5), 690–699 (2001).
   PubMed Web of Science ®Google Scholar
• Pappas PG, Alexander BD, Andes DR et al. Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin. Infect. Dis.50(8), 1101–1111 (2010).
   PubMed Web of Science ®Google Scholar
• Baddley JW, Perfect JR, Oster RA et al. Pulmonary cryptococcosis in patients without HIV infection: factors associated with disseminated disease. Eur. J. Clin. Microbiol. Infect. Dis.27(10), 937–943 (2008).
   PubMed Web of Science ®Google Scholar
• Almyroudis NG, Segal BH. Antifungal prophylaxis and therapy in patients with hematological malignancies and hematopoietic stem cell transplant recipients. Expert Rev. Anti Infect. Ther.8(12), 1451–1466 (2010).
   PubMed Web of Science ®Google Scholar
• Korfel A, Menssen HD, Schwartz S, Thiel E. Cryptococcosis in Hodgkin’s disease: description of two cases and review of the literature. Ann. Hematol.76(6), 283–286 (1998).
   PubMed Web of Science ®Google Scholar
• Binder U, Lass-Flörl C. Epidemiology of invasive fungal infections in the mediterranean area. Mediterr. J. Hematol. Infect. Dis.3(1), e20110016 (2011).
   PubMedGoogle Scholar
• Zinck SE, Leung AN, Fros M, Berry GJ, Muller NL. Pulmonary cryptococcosis: CT and pathologic findings. J. Comput. Assist. Tomogr.26, 330–334 (2002).
   PubMed Web of Science ®Google Scholar
• Tanner DC, Weinstein MP, Fedorciw B, Joho KL, Thorpe JJ, Reller L. Comparison of commercial kits for detection of cryptococcal antigen. J. Clin. Microbiol.32, 1680–1684 (1994).
   PubMed Web of Science ®Google Scholar
• Pagano L, Caira M, Falcucci P, Fianchi L. Fungal CNS infections in patients with hematologic malignancy. Expert Rev. Anti Infect. Ther.3(5), 775–785 (2005).
   PubMedGoogle Scholar
• Perfect JR, Dismukes WE, Dromer F et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america. Clin. Infect. Dis.50(3), 291–322 (2010).
   PubMed Web of Science ®Google Scholar
• Adler-Moore J, Proffitt RT. Effect of tissue penetration on AmBisome efficacy. Curr. Opin. Invest. Drugs4, 179–185 (2003).
   PubMedGoogle Scholar
• Tuon FF, Costa SF. Rhodotorula infection. A systematic review of 128 cases from literature. Rev. Iberoam. Micol.25(3), 135–140 (2008).
   PubMed Web of Science ®Google Scholar
• García-Suárez J, Gómez-Herruz P, Cuadros JA, Burgaleta C. Epidemiology and outcome of Rhodotorula infection in haematological patients. Mycoses54(4), 318–324 (2011).
   PubMed Web of Science ®Google Scholar
• Krcmery V, Krupova I, Denning DW. Invasive yeast infections other than Candida spp. in acute leukaemia. J. Hosp. Infect.41(3), 181–194 (1999).
   PubMed Web of Science ®Google Scholar
• Zaas AK, Boyce M, Schell W, Lodge BA, Miller JL, Perfect JR. Risk of fungemia due to Rhodotorula and antifungal susceptibility testing of Rhodotorula isolates. Clin. Microbiol.41(11), 5233–5235 (2003).
   Google Scholar
• Kiehn TE, Gorey E, Brown AE, Edwards FF, Armstrong D. Sepsis due to Rhodotorula related to use of indwelling central venous catheters. Clin. Infect. Dis.14(4), 841–846 (1992).
   PubMed Web of Science ®Google Scholar
• Kappe R, Schulze-Berge A. New cause for false-positive results with the Pastorex Aspergillus antigen latex agglutination test. J. Clin. Microbiol.31, 2489–2490 (1993).
   PubMed Web of Science ®Google Scholar
• Swanink CM, Meis JF, Rijs AJ, Donnelly JP, Verweij PE. Specificity of a sandwich enzyme-linked immunosorbent assay for detecting Aspergillus galactomannan. J. Clin. Microbiol.35, 257–260 (1997).
   PubMed Web of Science ®Google Scholar
• Gomez-Lopez A, Mellado E, Rodriguez-Tudela JL, Cuenca-Estrella M. Susceptibility profile of 29 clinical isolates of Rhodotorula spp. and literature review. J. Antimicrob. Chemother.55(3), 312–316 (2005).
   PubMed Web of Science ®Google Scholar
• García-Suárez J, Gómez-Herruz P, Cuadros JA, Guillén H, Burgaleta C. Rhodotorula mucilaginosa catheter-related fungaemia in a patient with multiple myeloma. Mycoses54(4), e214–e216 (2011).
   Google Scholar
• Diekema DJ, Petroelje B, Messer SA, Hollis RJ, Pfaller MA. Activities of available and investigational antifungal agents against Rhodotorula species. J. Clin. Microbiol.43(1), 476–478 (2005).
   PubMed Web of Science ®Google Scholar
• Lui AY, Turett GS, Karter DL, Bellman PC, Kislak JW. Amphotericin B lipid complex therapy in an AIDS patient with Rhodotorula rubra fungemia. Clin. Infect. Dis.27(4), 892–893 (1998).
   PubMedGoogle Scholar
• Tuon FF, de Almeida GM, Costa SF. Central venous catheter-associated fungemia due to Rhodotorula spp. – a systematic review. Med. Mycol.45(5), 441–447 (2007).
   PubMed Web of Science ®Google Scholar
• Lunardi LW, Aquino VR, Zimerman RA, Goldani LZ. Epidemiology and outcome of Rhodotorula fungemia in a tertiary care hospital. Clin. Infect. Dis.43(6), e60–e63 (2006).
   Web of Science ®Google Scholar
• Krcmery V Jr, Oravcova E, Spanik S et al. Nosocomial breakthrough fungaemia during antifungal prophylaxis or empirical antifungal therapy in 41 cancer patients receiving antineoplastic chemotherapy: analysis of aetiology risk factors and outcome. J. Antimicrob. Chemother.41(3), 373–380 (1998).
   PubMed Web of Science ®Google Scholar
• Bakir M, Cerikcioğlu N, Tirtir A, Berrak S, Ozek E, Canpolat C. Pichia anomala fungaemia in immunocompromised children. Mycoses47(5–6), 231–235 (2004).
   PubMed Web of Science ®Google Scholar
• Blaes AH, Cavert WP, Morrison VA. Malassezia: is it a pulmonary pathogen in the stem cell transplant population? Transpl. Infect. Dis.11(4), 313–317 (2009).
   Google Scholar
• Morrison VA, Weisdorf DJ. The spectrum of Malassezia infections in the bone marrow transplant population. Bone Marrow Transplant.26(6), 645–648 (2000).
   PubMed Web of Science ®Google Scholar
• Cassone M, Serra P, Mondello F et al. Outbreak of Saccharomyces cerevisiae subtype boulardii fungemia in patients neighboring those treated with a probiotic preparation of the organism. J. Clin. Microbiol.41(11), 5340–5343 (2003).
   PubMed Web of Science ®Google Scholar